Search / Trial NCT06221033

Comparing the Effects of Manual Hyperinflation and Diaphragmatic Proprioceptive Neuromuscular Facilitation on Pulmonary Functions in Patients on Mechanical Ventilation

Launched by OMAR HASHAM MOHAMED · Jan 14, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two different types of physiotherapy techniques to see which one helps improve lung function in male patients with Chronic Obstructive Pulmonary Disease (COPD) who are on mechanical ventilation. The two techniques being compared are Manual Hyperinflation (MHI) and Proprioceptive Neuromuscular Facilitation (PNF). The goal is to find out which method is more effective in helping these patients breathe better while they are receiving support from a ventilator.

To be eligible for this study, participants must be male, aged between 50 and 60, and currently receiving mechanical ventilation due to an acute exacerbation of COPD. They should also have a moderate to severe stage of COPD and a certain level of consciousness as measured by the Glasgow Coma Scale. However, individuals with specific health issues, such as active lung infections or certain recent surgeries, will not be included. Participants will experience either the MHI or PNF technique during the trial, and there will also be a control group for comparison. This study aims to provide valuable information that could lead to better treatment options for patients with COPD on mechanical ventilation.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • * Patients will be included in the study if they have the following criteria:
  • 1. Sixty male mechanically ventilated patients. They will be ventilated on pressure support (PS) mode of MV with this setting (Positive end-expiratory pressure \[PEEP\]) less than 8 cm H2O, FiO2 0.4 or less, SpO2 higher than 90) due to AECOPD.
  • 2. Their Glasgow Coma Scale score will be ranged from 13 to 15.
  • 3. Their age between 50 and 60 years old.
  • 4. Their BMI will be ranged from 25 to 34.9 kg/m2.
  • 5. Moderate (GOLD 2) and severe (GOLD 3) stages of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) grading system for the severity of COPD.
  • Exclusion Criteria:
  • * The patients will be excluded from this study if they have one of the following criteria:
  • Fever above 38.3 °C. Unstable hemodynamics. Thoracic or abdominal surgery that preclude the use of PNF exercises. Chest trauma such as rib fracture, flail chest and thoracic vertebra fracture or chest burns.
  • Peripheral and central nervous system diseases. Active lung infection like tuberculosis. Active bleeding as alveolar hemorrhage, hemoptysis. Spinal cord injuries involved the phrenic nerve. Severe cardiac complications due to COPD.

About Omar Hasham Mohamed

Omar Hasham Mohamed is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient outcomes through innovative study designs. With a focus on ethical standards and regulatory compliance, he collaborates with healthcare professionals and research institutions to facilitate rigorous clinical trials across various therapeutic areas. Leveraging a deep understanding of clinical protocols and patient needs, Omar strives to foster partnerships that drive scientific discovery and contribute to the development of safe and effective treatments. His vision emphasizes transparency, integrity, and a patient-centered approach in all aspects of clinical research.

Locations

Alexandria, Aleksandria, Egypt

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0